TikoMed appoints leading ALS expert Jeremy Shefner, Barrow Neurological Institute, Phoenix, Arizona to its Scientific Advisory Board (SAB)
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed Scientific Advisory Board.
Professor Shefner is a neurologist focusing on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as for a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association. He has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels.
“We are thrilled to welcome Dr. Shefner to join our SAB,” said Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed. “We are confident that his expertise within biomarker development for ALS diagnosis and experience from the NEALS consortium will be of great value for progressing our drug candidate ILB for treatment of ALS through the clinical program.”
Professor Shefner comments: “I am pleased to join the TikoMed Scientific Advisory Board, and look forward to assisting the company in reaching the next stage of clinical development. The company has an ambitious plan to design and implement a study with solid and reliable readouts to ensure accurate assessment of their experimental therapeutic agent.”
The SAB will advise management as Phase 2 clinical development of ILB progresses. The Board will integrate highly experienced clinicians as well as seasoned industrial scientific leaders in the field.
Contact
Adam Bruce, Founder, Chairman of the Board and CEO of Tikomed
Phone: +46-70-8238444
Email: adam.bruce@tikomed.com.
TikoMed AB
TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi-modal mechanism of action, TikoMed's drug platform has the potential to rebalance the body’s inflammatory, immune and fibrotic responses to acute and chronic inflammation to enhance self-repair and regeneration.
TikoMed’s initial development programs include Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation.
TikoMed’s highly scalable proprietary technology aims to provide innovative medicines to as many patients as possible across the globe.
TikoMed is privately-owned and based in Viken, Sweden. To learn more, visit www.tikomed.com
